TradeFlare's AI research teams analysed XERS on 8 market nights between August 3, 2026 and October 9, 2026. Each row is that night's verdict, the price that day, and how the price actually moved afterwards — wins and misses alike. Nothing is edited after the fact.
| Date | Verdict | Price | Target / stop | 5 days later | 20 days later | Why (that night) |
|---|---|---|---|---|---|---|
| October 9, 2026 | HOLD | $10.19 | — / — | not yet | not yet | The stock is being held due to a scanner trigger, but the current risk and technical factors do not support a buy. |
| October 8, 2026 | HOLD | $10.11 | — / — | not yet | not yet | The scanner trigger is based on a short-term post-earnings drift, suggesting a limited time horizon. |
| October 1, 2026 | BUY | $9.56 | $11.50 / $8.13 | +10.2% | not yet | The PEAD signal suggests a short-term catalyst. |
| September 29, 2026 | HOLD | $9.83 | — / — | +0.9% | not yet | The current setup does not warrant a BUY, and the market regime is neutral, suggesting caution. |
| August 6, 2026 | BUY | $8.11 | — / — | +13.2% | +16.7% | Continued positive news flow regarding patent extensions and product development. |
| August 5, 2026 | BUY | $8.19 | — / — | +4.7% | +5.8% | Strong Q1 2026 earnings and extended patent exclusivity for Keytruda biosimilar. |
| August 4, 2026 | BUY | $8.13 | — / — | +2.4% | +2.9% | Strong Q1 2026 financials and patent extensions provide a positive backdrop. |
| August 3, 2026 | BUY | $8.08 | — / — | -1.7% | +3.8% | Positive Q1 earnings and patent news have provided some recent optimism. |
Prices are daily closes. "Days later" counts trading days from the close on the day of the call. A HOLD is not a recommendation to buy; only published signals are tracked with a target and stop on the public record. How the research works. Updated October 14, 2026. AI-generated research for educational purposes — it can be wrong and is not financial advice.